Analyst Ratings January 28, 2026

Piper Sandler Starts Coverage of Shattuck Labs With Overweight Rating

Analyst sets $15 target for STTK, cites differentiated DR3 antibody program and encouraging preclinical data amid cash burn concerns

By Nina Shah STTK
Piper Sandler Starts Coverage of Shattuck Labs With Overweight Rating
STTK

Piper Sandler has begun coverage of Shattuck Labs (NASDAQ:STTK) with an Overweight rating and a $15.00 price target, signaling substantial upside from the current share price. The firm pointed to Shattuck’s SL-325, a Phase 1 DR3 monoclonal antibody aimed at inflammatory bowel disease, as the primary driver of its positive view while noting strong preclinical data and balance sheet characteristics that include more cash than debt but rapid cash consumption.

Key Points

  • Piper Sandler initiated coverage of Shattuck Labs with an Overweight rating and a $15.00 price target, implying substantial upside from the $4.02 share price.
  • SL-325, a DR3-targeting monoclonal antibody for IBD, is the focus of the bullish thesis; Piper Sandler cites robust non-human primate data and approximately 10 preclinical models supporting safety and lower anti-drug antibody expectations.
  • Shattuck shows more cash than debt on its balance sheet but is noted to be burning through cash quickly; current ratio reported at 17.0. H.C. Wainwright also upgraded the stock to Buy with a $6.00 target using a clinical net present value model assuming 10% probability of success.

Piper Sandler initiated coverage on Shattuck Labs (NASDAQ:STTK) with an Overweight recommendation and established a $15.00 price target, implying significant upside relative to the company’s trading level of $4.02. The research note highlights SL-325, Shattuck’s novel DR3-targeting monoclonal antibody in Phase 1 development, as the central catalyst behind the call.

The analyst report frames SL-325 as a differentiated approach to treating inflammatory bowel disease (IBD), observing that targeting the TL1A/DR3 axis has validation within the IBD therapeutic landscape. According to the research, roughly eight TL1A-directed agents are currently being developed, and receptor blockade through SL-325 is expected to deliver durable control of inflammation with a potentially greater inhibitory effect than competing modalities.

Piper Sandler underscored supporting preclinical evidence, citing robust non-human primate results and roughly 10 preclinical models that collectively point toward a favorable safety and tolerability profile. The firm also anticipates lower anti-drug antibody incidence relative to TL1A inhibitors as SL-325 moves into first-in-human testing.

The research house recommended that investors hold the stock ahead of two key clinical milestones: initial Phase 1 single ascending dose/multiple ascending dose data from healthy volunteer studies expected in the second quarter of 2026, followed by planned Phase 2 IBD trial initiations projected around the third quarter of 2026.

On the company’s financial position, InvestingPro data referenced in the coverage note indicate that Shattuck carries more cash than debt on its balance sheet. The same data, however, flag that the firm is expending cash at a rapid pace, and the company’s current ratio was noted at 17.0.

In a separate development cited in the coverage, H.C. Wainwright recently upgraded Shattuck Labs from Neutral to Buy and set a $6.00 price target. That upgrade was derived from a clinical net present value model applied to the SL-325 program, with the model representing full valuation contribution under an assumed 10% probability of success.

Shattuck’s market capitalization at the time of the note was reported as $254.38 million, and the stock has produced a return of 240.68% over the prior 12 months, illustrating notable momentum in the share price.

Investors and market participants will watch the company’s cash consumption, preclinical-to-clinical translation of SL-325, and the timing of the Phase 1 and Phase 2 data readouts as principal factors influencing the outlook for the stock.

Risks

  • Accelerating cash burn - the company is using cash at a rapid pace despite having more cash than debt, which could impact funding and operations if not managed; this affects the specialty finance and biotech funding environment.
  • Clinical risk - the H.C. Wainwright valuation applies a 10% probability of success to the SL-325 program, underscoring the low inherent probability of clinical and regulatory success for early-stage therapeutics; this impacts biotech investors and the healthcare sector.
  • Timing uncertainty - key catalysts are contingent on clinical milestones expected in 2026 (Phase 1 data in Q2 2026 and Phase 2 trial initiations around Q3 2026), and any delays could alter investor expectations and valuation.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026